Crossmark

RIFINs are adhesins implicated in severe Plasmodium falciparum malaria

Crossref DOI link: https://doi.org/10.1038/nm.3812

Published Online: 2015-03-09

Published Print: 2015-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Goel, Suchi

Palmkvist, Mia

Moll, Kirsten

Joannin, Nicolas

Lara, Patricia

R Akhouri, Reetesh

Moradi, Nasim

Öjemalm, Karin

Westman, Mattias

Angeletti, Davide

Kjellin, Hanna

Lehtiö, Janne

Blixt, Ola

Ideström, Lars

Gahmberg, Carl G

Storry, Jill R

Hult, Annika K

Olsson, Martin L

von Heijne, Gunnar https://orcid.org/0000-0002-4490-8569
Nilsson, IngMarie

Wahlgren, Mats
License Information

Text and Data Mining valid from 2015-03-09
More Information

Article History

Received: 6 October 2014

Accepted: 29 January 2015

First Online: 9 March 2015

Competing interests

: M. Wahlgren holds shares in and is a director of the board of Dilaforette AB, a company of the Karolinska Development AB involved in the development of adjunct treatment for severe malaria. The authors declare no other competing financial interests.